Rosuvastatin

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia, Hypertriglyceridemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (1)
JP
  • Crestor tablets 2.5 mg and 5 mg for hypercholesterolemia
shionogi.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (107)
Atherosclerotic Cardiovascular Disease
NCT07232069 · Duke University
2026-07-21 – 2031-07 · Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression, Prevention & Control, Premature Atherosclerosis
What this study did
NCT07736313 · Assiut University
2026-07-01 – 2029-09-01 · Acute Coronary Syndromes
What this study did
NCT07474649 · Daiichi Sankyo
2026-09-14 – 2028-10-02 · Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia
What this study did
NCT07930507 · AstraZeneca
2026-12-21 – 2027-10-11 · Hypercholesterolemia
What this study did
NCT07619131 · AstraZeneca
2026-08-12 – 2027-07-30 · Hypercholesterolaemia
What this study did
NCT07619118 · AstraZeneca
2026-09-10 – 2027-05-28 · Hypercholesterolaemia
What this study did
NCT07239414 · Sohaib Ashraf
2025-11-10 – 2027-02-21 · Cardiovascular
What this study did
NCT06772168 · CMG Pharmaceutical Co. Ltd
2024-04-19 – 2027-02-01 · Dyslipidemia, Type 2 Diabetes
What this study did
NCT04737408 · Bjarne Linde Noergaard
2020-05-13 – 2023-08 · Coronary Artery Disease
What this study did
NCT04964544 · AstraZeneca
2021-07-08 – 2023-03-01 · High Cholesterol
What this study did
NCT03510884 · Sanofi
2018-05-31 – 2022-08-05 · Hypercholesterolaemia
What this study did
NCT02662894 · EMS
2019-10 – 2020-12 · Hypertension, Dyslipidemia
What this study did
NCT02117453 · Assistance Publique - Hôpitaux de Paris
2014-10-27 – 2019-11-07 · ANCA-associated Primary Necrotizing Vasculitides
What this study did
NCT02546323 · AstraZeneca
2015-09-17 – 2019-01-29 · Atherosclerosis
What this study did
NCT03156842 · Boryung Pharmaceutical Co., Ltd
2017-05-29 – 2018-12-07 · Essential Hypertension, Dyslipidemia
What this study did
NCT02715726 · Sanofi
2016-07-27 – 2018-08-06 · Hypercholesterolemia
What this study did
NCT03009487 · Daewoong Pharmaceutical Co. LTD.
2017-01 – 2018-04 · Hypertension, Hyperlipidemias
What this study did
NCT03067688 · Yuhan Corporation
2017-04-11 – 2018-03-27 · Hypertension, Hyperlipidemia
What this study did
NCT02748057 · Organon and Co
2016-05-18 – 2017-12-11 · Hypercholesterolemia, Familial Hypercholesterolemia
What this study did
NCT03088254 · Jeil Pharmaceutical Co., Ltd.
2016-09-20 – 2017-12-04 · Dyslipidemia With Hypertension
What this study did
NCT03536598 · HK inno.N Corporation
2016-10-14 – 2017-09-04 · Hypertension With Hyperlipidemia
What this study did
NCT03210532 · Daewon Pharmaceutical Co., Ltd.
2016-10-07 – 2017-09 · Hypertension, Dyslipidemia
What this study did
NCT03566316 · IlDong Pharmaceutical Co Ltd
2015-11-24 – 2017-06-16 · Hypertension With Hyperlipidemia
What this study did
NCT02126358 · LG Life Sciences
2014-05 – 2016-03 · Type 2 Diabetes, Dyslipidemia
What this study did
NCT03288038 · Shin Poong Pharmaceutical Co. Ltd.
2014-10-13 – 2015-11-19 · Hypercholesterolemia
What this study did
NCT03571087 · Hanlim Pharm. Co., Ltd.
2014-09 – 2015-09 · Primary Hypercholesterolemia
What this study did
NCT02445352 · Alvogen Korea
2014-07 – 2015-03 · Primary Hypercholesterolemia
What this study did
NCT02087540 · IlDong Pharmaceutical Co Ltd
2013-05 – 2014-12 · Hypertension, Hyperlipidemia
What this study did
NCT01624857 · China National Center for Cardiovascular Diseases
2012-06 – 2014-06 · Coronary Heart Disease
What this study did
NCT01730053 · Regeneron Pharmaceuticals
2012-11-30 – 2014-05-31 · Hypercholesterolemia
What this study did
NCT01078675 · AstraZeneca
2010-02 – 2013-02 · Familial Hypercholesterolaemia
What this study did
NCT01378715 · University Hospital, Motol
2010-06 – 2012-08 · Coronary Artery Disease
What this study did
NCT02205775 · G. d'Annunzio University
2010-05 – 2012-06 · Stable Coronary Artery Disease Undergoing PCI
What this study did
NCT01936805 · Yuksek Ihtisas Hospital
2008-01 – 2012-01 · Atherosclerosis
What this study did
NCT00620542 · AstraZeneca
2008-01 – 2011-06 · Coronary Atherosclerosis
What this study did
NCT00854503 · University of Rome Tor Vergata
2008-09 – 2010-12 · Type 2 Diabetes, Diabetic Dyslipidemia
What this study did
NCT00783263 · Organon and Co
2008-11 – 2010-05 · Hypercholesterolemia
What this study did
NCT00683618 · AstraZeneca
2008-05 – 2009-07 · Hypercholesterolemia
What this study did
NCT00491530 · Abbott
2007-06 – 2008-11 · Mixed Dyslipidemia
What this study did
NCT00240279 · AstraZeneca
2003-01 – 2008-10 · Hypercholesterolemia
What this study did
NCT00525824 · AstraZeneca
2007-08 – 2008-09 · Hypercholesterolemia, Coronary Heart Disease, Atherosclerosis
What this study did
NCT00355615 · AstraZeneca
2006-07 – 2008-07 · Familial Hypercholesterolemia
What this study did
NCT00300430 · Abbott
2006-09 – 2008-03 · Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
What this study did
NCT00296387 · AstraZeneca
2006-01 – 2007-10 · Acute Coronary Syndrome
What this study did
NCT00214630 · AstraZeneca
2003-12 – 2007-08 · Acute Coronary Syndromes
What this study did
Phase 2/3 (18)
Atherosclerotic Cardiovascular Disease
NCT02979704 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2016-09 – 2017-07 · Hyperlipidemia
What this study did
Other / comorbidity
NCT07504198 · Tanta University
2026-03 – 2027-05 · Peripheral Nerve Disease
What this study did
NCT06696820 · Xiang Luo
2024-11-29 – 2026-06-03 · Acute Ischemic Stroke
What this study did
NCT07313124 · Beni-Suef University
2024-12-15 – 2025-12-01 · Cardiovascular Diseases (CVD)
What this study did
NCT04883840 · Universitaire Ziekenhuizen KU Leuven
2020-10-22 – 2025-10-11 · Ulcerative Colitis
What this study did
NCT03720067 · Universidade Federal do Rio de Janeiro
2019-01-25 – 2022-12-20 · Cirrhosis, Portal Hypertension, Variceal Hemorrhage
What this study did
NCT04491682 · Fudan University
2020-09-01 – 2022-06-20 · Atypical Endometrial Hyperplasia
What this study did
NCT04359095 · Universidad Nacional de Colombia
2020-08-18 – 2021-06-30 · COVID-19
What this study did
NCT03204058 · Government Dental College and Research Institute, Bangalore
2016-02-10 – 2017-02-23 · Chronic Periodontitis
What this study did
NCT02985099 · Government Dental College and Research Institute, Bangalore
2015-11 – 2016-07 · Chronic Periodontitis, Type2 Diabetes
What this study did
NCT03043196 · Government Dental College and Research Institute, Bangalore
2015-06 – 2016-04 · Chronic Periodontitis
What this study did
NCT02800902 · Government Dental College and Research Institute, Bangalore
2015-05 – 2016-02 · Chronic Periodontitis
What this study did
NCT03521700 · Chinese Academy of Medical Sciences, Fuwai Hospital
2013-06-01 – 2015-12-30 · Renal Artery Obstruction, Stents, Lipids, Glomerular Filtration Rate, Blood Pressure
What this study did
NCT02645227 · Government Dental College and Research Institute, Bangalore
2015-01 – 2015-10 · Chronic Periodontitis
What this study did
NCT02600520 · Government Dental College and Research Institute, Bangalore
2014-11 – 2015-05 · Chronic Periodontitis
What this study did
NCT00986999 · University of Hawaii
2009-09 – 2015-01 · HIV Infections, Cardiovascular Disease
What this study did
NCT02283515 · Government Dental College and Research Institute, Bangalore
2014-01 – 2014-06 · Chronic Periodontitis
What this study did
Phase 2 (49)
Atherosclerotic Cardiovascular Disease
NCT06488105 · Wake Forest University Health Sciences
2024-08-05 – 2029-03-31 · Lipid Disorder, Hypercholesterolemia, Cardiovascular Diseases, Atherosclerosis
What this study did
NCT04846231 · The Cleveland Clinic
2021-04-23 – 2022-07-19 · Hypercholesterolemia
What this study did
NCT02841774 · Matthew Feinstein
2016-11 – 2021-06 · HIV Infection, Coronary Heart Disease
What this study did
NCT01837823 · Icahn School of Medicine at Mount Sinai
2013-07 – 2015-04 · Obstructive Coronary Artery Disease, Coronary Artery Disease
What this study did
NCT01170585 · Imperial College London
2010-07 – 2014-06 · Atherosclerosis, Systemic Lupus Erythematosus
What this study did
NCT01863225 · Resverlogix Corp
2013-05 – 2013-06 · Dyslipidemia, Coronary Artery Disease
What this study did
NCT00296400 · AstraZeneca
2006-02 – 2009-06 · Hyperlipidemia
What this study did
NCT00693589 · Insel Gruppe AG, University Hospital Bern
2005-01 – 2007-04 · Cardiovascular Disease, Endothelial Dysfunction
What this study did
NCT00160745 · University of Erlangen-Nürnberg Medical School
est. completion 2006-09 · Hypercholesterolemia
What this study did
NCT00184951 · Radboud University Medical Center
2004-04 – 2005-07 · HIV Infections, Hyperlipidemia
What this study did
Other / comorbidity
NCT05832229 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2023-12-07 – 2029-08-31 · Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
What this study did
NCT05483010 · Washington University School of Medicine
2024-02-19 – 2028-05-31 · Clonal Cytopenia of Undetermined Significance, Myelodysplastic Syndromes
What this study did
NCT07460960 · Lomonosov Moscow State University Medical Research and Educational Center
2026-03-05 – 2027-12 · Erectile Dysfunction Due to Arterial Disease, Atheroscleroses, Erectile Disfunction, Endothelial Dysfunction, Androgen Profile, Testosterone
What this study did
NCT06924684 · Sheikh Zayed Federal Postgraduate Medical Institute
2024-12-02 – 2025-07-02 · ST Elevation (STEMI) Myocardial Infarction
What this study did
NCT04491643 · Fudan University
2020-09-01 – 2025-04-11 · Endometrial Carcinoma Stage I
What this study did
NCT04824911 · Chang Gung Memorial Hospital
2021-03-23 – 2025-02-28 · Acute Stroke, Dual Antiplatelet Therapy, Statin
What this study did
NCT03532139 · Beth Israel Deaconess Medical Center
2018-07-25 – 2024-05-31 · Ovarian Cancer
What this study did
NCT04303806 · Assiut University
2020-10 – 2023-12 · Preeclampsia
What this study did
NCT05895123 · Damanhour University
2021-11-01 – 2023-04-01 · ST-segment Elevation Myocardial Infarction
What this study did
NCT03113994 · Dr. B. Catharine. Craven
2018-02-26 – 2022-12-31 · Spinal Cord Injuries, Osteoporosis, Metabolic Syndrome
What this study did
NCT02569645 · AHS Cancer Control Alberta
2015-11 – 2021-09-24 · Rectal Cancer
What this study did
NCT02901067 · Denver Health and Hospital Authority
2017-02-03 – 2021-08-01 · Wounds and Injuries, Venous Thromboembolism
What this study did
NCT04817904 · Cairo University
2020-11-17 – 2021-08 · Cisplatin Adverse Reaction
What this study did
NCT04504851 · National University Hospital, Singapore
2020-08-12 – 2021-03-31 · Pulmonary Tuberculosis
What this study did
NCT02679664 · Ottawa Hospital Research Institute
2016-11 – 2020-07 · Venous Thromboembolism
What this study did
NCT01863914 · National Cheng-Kung University Hospital
2012-11 – 2019-01-31 · End-stage Kidney Disease, Diabetes Mellitus, Arteriovenous Fistula
What this study did
NCT02516826 · Samsung Medical Center
2015-08 – 2018-08 · Coronary Syndrome
What this study did
NCT01524653 · University of Vermont
2012-03 – 2016-09-01 · Venous Thromboembolism, Deep Vein Thrombosis, Neoplasms
What this study did
NCT01218802 · University Hospitals Cleveland Medical Center
2011-02 – 2014-05 · HIV Infections, Heart Disease
What this study did
NCT02129231 · University of Guadalajara
2012-02 – 2014-04 · Oxidative Stress, Diabetic Polyneuropathy
What this study did
NCT01526460 · IRCCS San Raffaele
2011-08 – 2014-02 · Platelet Dysfunction
What this study did
NCT00929734 · University Hospital, Akershus
2010-03 – 2014-01 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT00951132 · University Hospital, Akershus
2009-09 – 2013-12 · Depression
What this study did
NCT01299038 · Beth Israel Deaconess Medical Center
2010-10 – 2013-12 · Breast Cancer
What this study did
NCT01874743 · Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
2012-03 – 2013-09 · HIV-1 Infection
What this study did
NCT01923077 · Svendborg Hospital
2010-04 – 2013-09 · Acute Myocardial Infarction
What this study did
NCT00357123 · Universidad Autonoma de San Luis Potosí
2006-08 – 2011-09 · Sepsis
What this study did
NCT01622777 · Alejandra Guillermina Miranda Diaz
2010-02 – 2011-06 · Diabetic Polyneuropathy
What this study did
NCT00978419 · Vanderbilt University Medical Center
2010-03 – 2011-05 · Burns
What this study did
NCT00487318 · Bader, Ted, M.D.
2007-06 – 2010-10 · Chronic Hepatitis C
What this study did
NCT01798602 · Canadian Critical Care Trials Group
2009-12 – 2010-08 · H1N1 Influenza
What this study did
NCT01033955 · Canadian Critical Care Trials Group
2010-01 – 2010-07 · Critically Ill, H1N1/Influenza Infection
What this study did
NCT00555230 · Chinese University of Hong Kong
2007-07 – 2009-12 · Rheumatoid Arthritis
What this study did
NCT00296374 · AstraZeneca
2006-02 – 2009-03 · Diabetes Mellitus
What this study did
NCT00329758 · Universidad Autonoma de San Luis Potosí
2006-07 – 2007-10 · Head Injury
What this study did
NCT00315510 · Radboud University Medical Center
2006-04 – 2007-08 · Ischemia
What this study did
NCT00446940 · Bader, Ted, M.D.
2006-12 – 2007-03 · Hepatitis C
What this study did
NCT00176332 · University of Leipzig
2004-03 – 2006-12 · Heart Failure
What this study did
NCT00364559 · Universidad Autonoma de San Luis Potosí
2006-08 – 2006-12 · Intracerebral Hemorrhage, Stroke
What this study did
Phase 1/2 (4)
Other / comorbidity
NCT04833764 · Khanh Nguyen
2021-06-01 – 2025-06-01 · Post-thrombotic Syndrome, Deep Vein Thrombosis Leg
What this study did
NCT02314286 · Soroka University Medical Center
2014-12 – 2016-07 · Severe Pre-eclampsia
What this study did
NCT00990028 · Universidad Autonoma de San Luis Potosí
2009-08 – 2011-08 · Head Injury
What this study did
NCT00885495 · University of Cincinnati
2009-01 – 2010-08 · HIV Infections
What this study did
Phase 1 (270)
Atherosclerotic Cardiovascular Disease
NCT07309042 · Beijing Inno Medicine Co., Ltd.
2025-12-08 – 2026-03-30 · Atherosclerotic Cardiovascular Diseases, Cerebrovascular Diseases
What this study did
NCT07001787 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2025-06 – 2026-03 · Dyslipidemia
What this study did
NCT07097831 · Shandong Suncadia Medicine Co., Ltd.
2025-10-09 – 2025-11-07 · Hyperlipidemia
What this study did
NCT05384262 · AstraZeneca
2022-05-18 – 2024-06-14 · Dyslipidemia
What this study did
NCT06475872 · Hanlim Pharm. Co., Ltd.
2023-11-20 – 2023-12-07 · Primary Hypercholesterolemia, Combined Hyperlipidemia
What this study did
NCT05787002 · AstraZeneca
2023-03-09 – 2023-05-15 · Dyslipidemia
What this study did
NCT03867942 · LG Chem
2019-03-21 – 2019-08-31 · Diabetes Mellitus, Type 2, Dyslipidemias
What this study did
NCT03707899 · Jeil Pharmaceutical Co., Ltd.
2018-12-13 – 2019-05-22 · Hypertension With Dyslipidemia
What this study did
NCT03690778 · Jeil Pharmaceutical Co., Ltd.
2018-10-04 – 2019-02-01 · Diabetes, Hyperlipidemias
What this study did
NCT02982798 · Jeil Pharmaceutical Co., Ltd.
2017-07-06 – 2018-01-31 · Diabetes, Hyperlipidemia
What this study did
NCT02364258 · Children's Mercy Hospital Kansas City
2014-07 – 2017-12-27 · Dyslipidemia
What this study did
NCT03247140 · Jeil Pharmaceutical Co., Ltd.
2017-06-10 – 2017-11-27 · Hypertension With Dyslipidemia
What this study did
NCT03175835 · Chong Kun Dang Pharmaceutical
2017-05-08 – 2017-06-19 · Dyslipidemias
What this study did
NCT02995720 · Boryung Pharmaceutical Co., Ltd
2016-08-26 – 2017-05-30 · Hypertension, Hyperlipidemia
What this study did
NCT03116516 · Yuhan Corporation
2017-04-21 – 2017-05-26 · Hypertension, Hyperlipidemia
What this study did
NCT02951962 · Yuhan Corporation
2016-08 – 2016-09 · Hypertension, Hyperlipidemia
What this study did
NCT02789475 · Alvogen Korea
2016-05 – 2016-07 · Hypertension, Hyperlipidemias
What this study did
NCT02569814 · Boryung Pharmaceutical Co., Ltd
2015-09 – 2015-12 · Hypertension, Hyperlipidemia
What this study did
NCT02933658 · Daewon Pharmaceutical Co., Ltd.
2015-11 – 2015-11 · Hypertension and Dyslipidemia
What this study did
NCT02387619 · Jeil Pharmaceutical Co., Ltd.
2015-02 – 2015-07 · Hypertension, Hyperlipidemia
What this study did
NCT03009474 · HK inno.N Corporation
2015-02 – 2015-04 · Hypertension, Hyperlipidemias
What this study did
NCT01955759 · Heart Center BH Tuzla
2013-12 – 2015-02 · Patients With Coronary Artery Disease Scheduled for by Pass Surgery
What this study did
NCT02186483 · Jeil Pharmaceutical Co., Ltd.
2014-08 – 2015-02 · Hyperlipidemia, Diabetes
What this study did
NCT02089061 · Bristol-Myers Squibb
2014-03 – 2014-05 · Acute Coronary Syndromes
What this study did
NCT02047175 · Chong Kun Dang Pharmaceutical
2014-02 – 2014-03 · Hypertension, Hyperlipidemia
What this study did
NCT02029625 · NVP Healthcare
2014-02 – 2014-03 · Dyslipidemia
What this study did
NCT01241903 · Susan Smyth
2011-06 – 2014-02 · Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Blood Platelets
What this study did
NCT02859129 · AstraZeneca
2013-09 – 2013-11 · Hypertriglyceridemia
What this study did
NCT01975961 · Yuhan Corporation
2013-07 – 2013-09 · Dyslipidemia & Hypertension
What this study did
NCT01711749 · GlaxoSmithKline
2013-02-25 – 2013-03-13 · Hypercholesterolaemia
What this study did
NCT01609907 · Yuhan Corporation
2011-11 – 2012-05 · Hypertension, Hyperlipidemia
What this study did
NCT01918709 · LG Life Sciences
2011-09 – 2011-11 · Hypertension, Hyperlipidemia
What this study did
NCT00689416 · AstraZeneca
2007-12 – 2009-06 · Atherosclerosis, Inflammatory Activity in Carotid Arteries
What this study did
NCT00783042 · AstraZeneca
2008-10 – 2009-05 · Atherosclerosis, Inflammatory Activity in Coronary Arteries
What this study did
NCT00585143 · AstraZeneca
2008-01 – 2008-10 · Dyslipidemia, Renal Insufficiency
What this study did
NCT00651144 · Organon and Co
2003-03 – 2003-05 · Hypercholesterolemia, Atherosclerosis
What this study did
Other / comorbidity
NCT07912268 · Jiangsu Simcere Pharmaceutical Co., Ltd.
2026-11-01 – 2029-06-01 · ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
NCT06538649 · Stanford University
2024-12-12 – 2028-10-31 · Crohn's Ileocolitis, Crohn Disease
What this study did
NCT06899061 · AstraZeneca
2025-03-25 – 2028-05-19 · Advanced Solid Malignancies
What this study did
NCT05912387 · Stanford University
2023-05-31 – 2027-12-31 · Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
What this study did
NCT04903223 · Children's Mercy Hospital Kansas City
2021-04-01 – 2027-12-31 · Cholesterol; Lipidosis
What this study did
NCT02592317 · Aragon Pharmaceuticals, Inc.
2016-02-12 – 2027-12-31 · Prostatic Neoplasms, Castration-Resistant
What this study did
NCT05614739 · Eli Lilly and Company
2023-01-12 – 2027-06 · Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
What this study did
Phase 4 (140)
Atherosclerotic Cardiovascular Disease
NCT07799779 · Seoul National University Bundang Hospital
2026-11-30 – 2029-09 · Acute Coronary Syndromes (ACS)
What this study did
NCT06186037 · Saint Vincent's Hospital, Korea
2024-02-01 – 2029-02-28 · Coronary Artery Disease, Dyslipidemias, Primary Prevention
What this study did
NCT06767345 · Korea University Anam Hospital
2025-05-12 – 2028-06-25 · Coronary Artery Disease, Atherosclerosis of Coronary Artery, Plaque, Atherosclerotic
What this study did
NCT05850091 · Massachusetts General Hospital
2023-12-07 – 2027-06-01 · Coronary Artery Disease
What this study did
NCT03169985 · Samsung Medical Center
2017-07-12 – 2027-01-28 · Coronary Artery Disease
What this study did
NCT06765265 · King Edward Medical University
2025-01-05 – 2026-01-01 · Acute Coronary Syndromes
What this study did
NCT03988101 · Yonsei University
2019-09-19 – 2025-05-30 · Venous Thromboembolism, Dyslipidemias
What this study did
NCT06262685 · Instituto de Investigación Hospital Universitario La Paz
2024-03-04 – 2025-03-04 · Cardiovascular Diseases, Dyslipidemias, Statin Adverse Reaction, Pharmacogenic Myopathy
What this study did
NCT05661552 · Yonsei University
2022-12-01 – 2025-02-05 · Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
What this study did
NCT06153433 · Yonsei University
2023-11-06 – 2024-08 · Dyslipidemia
What this study did
NCT04700436 · Seoul National University Hospital
2020-01-03 – 2024-02-13 · Endocrine System Diseases, Nutritional and Metabolic Diseases, Diabetes Mellitus, Type 2, Dyslipidemias
What this study did
NCT06053983 · Rawalpindi Medical College
2023-01-01 – 2023-08-01 · Mi Q Wave
What this study did
NCT04826354 · Korea University Anam Hospital
2021-08-11 – 2023-06-28 · Atheroscleroses, Coronary
What this study did
NCT03233243 · University of Coimbra
2020-07-27 – 2022-10-27 · Cardiovascular Diseases, Atherosclerosis, Molecular Imaging
What this study did
NCT03418974 · Fudan University
2017-11-01 – 2021-12-31 · Dyslipidemias
What this study did
NCT03993236 · Keun-Sik Hong
2019-09-09 – 2021-09-27 · Stroke, Ischemic
What this study did
NCT03657758 · Kobe University
2018-09-17 – 2021-08-31 · Coronary Artery Disease, Angina Pectoris
What this study did
NCT02772640 · Collegium Medicum w Bydgoszczy
2016-03 – 2020-05 · Hypercholesterolemia
What this study did
NCT03784703 · Damanhour University
2018-01-01 – 2020-01-31 · Dyslipidemia Associated With Type II Diabetes Mellitus
What this study did
NCT02859480 · Korea University Anam Hospital
2015-09 – 2019-12 · Coronary Artery Disease, Coronary Disease, Cardiovascular Diseases
What this study did
NCT03007524 · Nanjing First Hospital, Nanjing Medical University
2016-07 – 2019-12 · Acute Coronary Syndrome
What this study did
NCT03434613 · Yonsei University
2018-05-14 – 2019-09-11 · Nonalcoholic Fatty Liver Disease, Dyslipidemias
What this study did
NCT02594800 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2015-12-21 – 2019-06-30 · Atherosclerosis
What this study did
NCT03217409 · Yuhan Corporation
2017-08-10 – 2019-05-23 · Diabetes Mellitus and Hypercholesterolemia
What this study did
NCT01813357 · Bayside Health
2013-07-02 – 2018-11-01 · HIV, Cardiovascular Disease
What this study did
NCT02984982 · Sanofi
2016-11-15 – 2018-07-27 · Hypercholesterolemia, Acute Coronary Syndrome
What this study did
NCT03949374 · Yonsei University
2015-10-23 – 2018-06-01 · Hypercholesterolemia, Dyslipidemias
What this study did
NCT02458755 · Samsung Medical Center
2012-02 – 2018-06 · Stroke, Intracranial Atherosclerosis
What this study did
NCT02532309 · Wei Liu
2015-04 – 2018-04 · Carotid Atherosclerosis
What this study did
NCT03074630 · Amsterdam UMC, location VUmc
2016-05 – 2018-04 · Diabetes Mellitus, Type 2, Hypercholesterolemia
What this study did
NCT02418884 · Sir Run Run Shaw Hospital
2015-04 – 2018-03 · Coronary Artery Disease
What this study did
NCT03192579 · Kobe University
2013-07-26 – 2017-06-02 · Coronary Artery Disease Progression
What this study did
NCT02593487 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
2015-11 – 2017-06 · Hyperlipemia, Coronary Heart Disease
What this study did
NCT01382472 · Helse Stavanger HF
2011-09 – 2016-12 · ST Elevation (STEMI) Myocardial Infarction
What this study did
NCT01870804 · Centro Cardiopatici Toscani
2013-05 – 2016-09 · Acute Coronary Syndrome
What this study did
NCT02284503 · Shanghai Zhongshan Hospital
2014-11 – 2016-06 · Non-ST-elevation Acute Coronary Syndromes
What this study did
NCT02077257 · Committee of Cardio-Cerebral-Vascular Diseases of GSC
2014-03 – 2016-05 · Acute Coronary Syndrome
What this study did
NCT00923676 · University of Campania Luigi Vanvitelli
2008-04 – 2016-04 · Sexual Dysfunction, Hyperlipidemia
What this study did
NCT01325818 · Yokohama City University Medical Center
2011-03 – 2016-02 · Coronary Disease, Hypercholesterolemia
What this study did
NCT01697735 · Wenzhou Medical University
2012-09 – 2015-09 · Dyslipidemias
What this study did
NCT03011775 · Ukrainian Medical Stomatological Academy
2012-11 – 2015-09 · Adverse Effect, Atherosclerosis, Coronary, Insulin Resistance Syndrome
What this study did
NCT01773512 · General University Hospital, Prague
2012-06 – 2015-06 · Coronary Artery Disease
What this study did
NCT01567774 · University of Roma La Sapienza
2012-04 – 2015-06 · Coronary Artery Disease
What this study did
NCT02280590 · Dong-A ST Co., Ltd.
2014-09 – 2015-06 · Hyperlipidemia
What this study did
NCT00997880 · Seung-Jung Park
2010-04 – 2014-12 · Coronary Artery Disease
What this study did
NCT01613729 · D16 Pharma & Biotec Ltd.
2012-07 – 2013-12 · Dyslipidemia
What this study did
NCT01968577 · Kleber Bomfim Araujo Martins
2011-03 – 2013-12 · Coronary Artery Disease
What this study did
NCT01660919 · Gachon University Gil Medical Center
2011-10 – 2013-12 · Hypercholesterolemia
What this study did
Early phase / not applicable (36)
Atherosclerotic Cardiovascular Disease
NCT06603363 · Prof. Maurovich-Horvat Pál
2025-05-28 – 2028-12-15 · Coronary Artery Disease, Atherosclerotic Plaque, Coronary Computed Tomography Angiography, Statin Therapy, Multidetector Computed Tomography, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis, Vascular Diseases, Hyperlipidemia
What this study did
NCT07401017 · Taipei Medical University WanFang Hospital
2026-03-01 – 2026-10-31 · Dyslipidemia, Long-Distance Running, Endurance Training, Statin-Associated Muscle Symptoms
What this study did
NCT04626973 · Yonsei University
2021-01-15 – 2025-09-24 · Atherosclerotic Cardiovascular Disease
What this study did
NCT03355027 · Cambridge University Hospitals NHS Foundation Trust
2017-11-30 – 2023-11-30 · Atherosclerosis, Cardiovascular Diseases
What this study did
NCT04744571 · Beijing Anzhen Hospital
2021-02 – 2023-01 · Coronary Artery Disease, Coronary Occlusion, Percutaneous Coronary Intervention, Chronic Total Occlusion of Coronary Artery, Drug-Eluting Stents
What this study did
NCT04176978 · Chinese University of Hong Kong
2021-04-01 – 2022-12-31 · Psoriatic Arthritis, Atherosclerosis
What this study did
NCT05306990 · Helwan University
2017-04-20 – 2021-01-31 · Hydroxymethylglutaryl-CoA Reductase Inhibitors, Diabetes Mellitus
What this study did
NCT02433288 · AstraZeneca
2015-07-20 – 2016-10-28 · Dyslipidemia, Hyperlipidemia
What this study did
NCT02420899 · Beijing Friendship Hospital
2015-04 – 2016-07 · Acute Coronary Syndrome
What this study did
NCT01653119 · Peking University Third Hospital
2012-04 – 2015-12 · Acute Coronary Syndrome, Diabetes Mellitus
What this study did
NCT00908011 · University of British Columbia
2009-06 – 2015-01 · Hypercholesterolemia, HIV Infections
What this study did
NCT01173939 · Positive Trial Group
2010-07 – 2014-06 · Hypercholesterolemia, Type 2 Diabetes, Hypertension
What this study did
NCT01544309 · Listen Trial Group
2012-03 – 2014-06 · Hypercholesterolemia With Concomitant Type 2 Diabetes
What this study did
NCT01982461 · Pin Siang Medical Biotechnology Co., Ltd.
2013-11 – 2014-01 · Hypercholesterolemia
What this study did
NCT01547377 · Universidade Federal do Rio Grande do Norte
2008-01 – 2009-11 · Dietary Selenium Deficiency, Dietary Zinc Deficiency
What this study did
Other / comorbidity
NCT07568574 · Enhanced Emirates Limited
2026-03-12 – 2033-03-01 · Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
What this study did
NCT07748273 · Hospital das Clínicas de Ribeirão Preto
2026-08-02 – 2027-05-15 · Obesity & Overweight, Bariatric Surgery, Pharmacokinetics After Oral Intake, Drug Absorption
What this study did
NCT07717788 · Alkufa university\\collage of pharmacy
2025-02-01 – 2026-07-01 · Osteoporosis, Postmenopausal, Statin Therapy
What this study did
NCT04699279 · Nanjing Medical University
2021-01-01 – 2024-12-31 · Acute Aortic Syndrome, Aortopathy
What this study did
NCT06910098 · Central Park Medical College
2023-12-01 – 2024-08-31 · LDL - Low Density Lipoprotein Receptor Disorder, Rosuvastatin
What this study did
NCT04974814 · Beni-Suef University
2021-05-26 – 2023-04 · ST Elevation Myocardial Infarction
What this study did
NCT05637060 · University of Karachi
2022-11-24 – 2022-12-15 · Healthy Individuals
What this study did
NCT06094244 · Pomeranian Medical University Szczecin
2017-03-17 – 2021-03-17 · Intracerebral Hemorrhage
What this study did
NCT02341794 · Tokyo Medical University
2015-01 – 2018-07 · Intracranial Arterial Diseases
What this study did
NCT02305862 · Capital Medical University
2013-01 – 2017-07 · Arteriosclerosis, Diabetes Mellitus, Lipid Disorder
What this study did
NCT01613794 · Leiden University Medical Center
2012-12 – 2016-12 · Deep Vein Thrombosis, Pulmonary Embolism
What this study did
NCT01623921 · Tel-Aviv Sourasky Medical Center
2012-08 – 2013-08 · Blunt Chest Trauma, Acute Respiratory Distress Syndrome
What this study did
NCT01389388 · Diakonhjemmet Hospital
2013-01 – 2013-08 · Carotid Artery Plaque, Ankylosing Spondylitis, Rheumatoid Arthritis
What this study did
NCT00970606 · Gordon Bernard
2009-10 – 2011-07 · Acute Respiratory Distress Syndrome, Influenza, H1N1 Influenza
What this study did
NCT04328064 · University of Alexandria
2010-05 – 2011-06 · Behcet's Disease
What this study did
NCT00554138 · Radboud University Medical Center
2007-11 – 2008-04 · Adenosine Metabolism
What this study did
NCT00464503 · Universiteit Antwerpen
2007-09 – 2007-10 · Statin Induced Proteinuria
What this study did
NCT00371579 · UMC Utrecht
2006-10 – 2007-10 · Hepatitis C
What this study did
Used as active comparator (52)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (27)
Atherosclerotic Cardiovascular Disease
NCT04602754 · EMS
2023-12-01 – 2027-09 · Dyslipidemia Associated With Type II Diabetes Mellitus
What this study did
NCT07216482 · Merck Sharp & Dohme LLC
2025-11-11 – 2026-10-27 · Hyperlipidemia
What this study did
NCT04603508 · EMS
2023-03 – 2025-08 · Type 2 Diabetes Mellitus, Dyslipidemia
What this study did
NCT03527069 · EMS
2021-01-29 – 2025-07-25 · Hypertriglyceridemia, Dyslipidemia
What this study did
NCT03540355 · EMS
2021-03-02 – 2025-01-23 · Dyslipidemias
What this study did
NCT02827903 · Jeil Pharmaceutical Co., Ltd.
2016-01-15 – 2018-03-16 · Type 2 Diabetes, Dyslipidemia
What this study did
NCT02586129 · Yuhan Corporation
2015-11-04 – 2017-07-07 · Dyslipidemia, Type II Diabetes
What this study did
NCT02741245 · Organon and Co
2016-06-09 – 2017-01-18 · Hypercholesterolemia
What this study did
NCT02390375 · Daewon Pharmaceutical Co., Ltd.
2014-11 – 2016-05 · Hypercholesterolemia
What this study did
NCT01914432 · Yuhan Corporation
2013-11 – 2014-06 · Hyperlipidemia, Hypertension
What this study did
NCT01730040 · Regeneron Pharmaceuticals
2012-10 – 2014-05 · Hypercholesterolemia
What this study did
NCT01763866 · Amgen
2013-01-15 – 2013-12-04 · Hyperlipidemia
What this study did
NCT01764295 · Daewoong Pharmaceutical Co. LTD.
2012-09 – 2013-07 · Hypertension, Dyslipidemia
What this study did
NCT01918332 · LG Life Sciences
2012-04 – 2013-03 · Hypertension,, Hyperlipidemia
What this study did
NCT01154036 · Organon and Co
2010-07 – 2012-10 · Hypercholesterolemia
What this study did
NCT00664469 · Sunnybrook Health Sciences Centre
2007-08 – 2010-11 · Hypercholesterolemia
What this study did
NCT00462748 · Organon and Co
2007-03 – 2008-06 · Hypercholesterolemia
What this study did
NCT00463606 · AstraZeneca
2007-04 – 2008-02 · Hypercholesterolemia, Dyslipidemia
What this study did
Other / comorbidity
NCT03016819 · Advenchen Laboratories, LLC
2017-08-15 – 2028-12 · Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
What this study did
NCT05731596 · Tanta University
2023-06 – 2024-04 · Nonalcoholic Steatohepatitis
What this study did
NCT02770261 · Alvogen Korea
2015-12 – 2016-10 · Hypertension, Cholesterolemia
What this study did
NCT01228227 · Gennaro Sardella
2010-10 – 2011-08 · Assess the Periprocedural Myocardial Necrosis
What this study did
NCT00862251 · Organon and Co
2009-04 – 2011-03 · Cardiovascular Disorder, Diabetes Mellitus
What this study did
NCT00718796 · The Canadian College of Naturopathic Medicine
2008-04 – 2009-10 · Cardiovascular Disease
What this study did
Phase 2/3 (1)
Atherosclerotic Cardiovascular Disease
NCT06834932 · AstraZeneca
2024-12-06 – 2027-02-22 · Dyslipidaemia
What this study did
Phase 2 (4)
Atherosclerotic Cardiovascular Disease
NCT07307989 · Chang Gung Memorial Hospital
2025-08-01 – 2029-07-31 · Ischemic Stroke, Hypercholesteremia
What this study did
NCT02977065 · Chong Kun Dang Pharmaceutical
2017-03-23 – 2018-01-30 · Dyslipidemias
What this study did
NCT01970215 · Xention Ltd
2013-08 – 2014-07 · Dyslipidemia
What this study did
NCT01105975 · Eli Lilly and Company
2010-04 – 2011-06 · Dyslipidemia
What this study did
Phase 1/2 (1)
Atherosclerotic Cardiovascular Disease
NCT06048588 · Beijing Inno Medicine Co., Ltd.
2023-10-08 – 2025-04-27 · Atherosclerotic Cardiovascular Disease
What this study did
Phase 1 (10)
Atherosclerotic Cardiovascular Disease
NCT02608242 · Yuhan Corporation
2015-11 – 2016-06 · Hypertension, Hyperlipidemia
What this study did
Other / comorbidity
NCT02026817 · Hanmi Pharmaceutical Company Limited
2013-12 – 2014-01 · Diabetes Mellitus
What this study did
NCT02011633 · Hanmi Pharmaceutical Company Limited
2013-10 – 2013-12 · Diabetes Mellitus
What this study did
NCT01929512 · Hanmi Pharmaceutical Company Limited
2013-06 – 2013-08 · Diabetes Mellitus
What this study did
NCT01493856 · Daewoong Pharmaceutical Co. LTD.
2012-01 – 2012-03 · Healthy Volunteers
What this study did
NCT00681395 · AstraZeneca
2008-05 – 2008-08 · Adverse Events, Pharmacokinetic
What this study did
Phase 4 (6)
Atherosclerotic Cardiovascular Disease
NCT04433533 · Yonsei University
2021-01-06 – 2023-12 · Left Ventricular Diastolic Dysfunction, Hyperlipidemias
What this study did
NCT04056169 · Yuhan Corporation
2017-06-29 – 2019-07-23 · Acute Coronary Syndrome, Carotid Atherosclerotic Plaque With Inflammation
What this study did
NCT01023607 · Harbin Medical University
2009-12 – 2013-08 · Coronary Artery Disease, Hyperlipidemia
What this study did
Other / comorbidity
NCT05613426 · Henan Institute of Cardiovascular Epidemiology
2023-04-03 – 2026-05-16 · ST Elevation Myocardial Infarction (STEMI)
What this study did
NCT05072054 · Post Graduate Institute of Medical Education and Research, Chandigarh
2019-10-16 – 2022-08-31 · Heart Failure With Reduced Ejection Fraction
What this study did
Early phase / not applicable (3)
Atherosclerotic Cardiovascular Disease
NCT07626840 · Samsung Medical Center
2026-06-01 – 2031-12-31 · Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
What this study did
Other / comorbidity
NCT03044665 · Yonsei University
2017-03-15 – 2023-02-15 · Cardiovascular Diseases, Cerebrovascular Disease, Peripheral Atherosclerotic Disease
What this study did
Studied as part of a combination product (16)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (11)
Atherosclerotic Cardiovascular Disease
NCT06646354 · Hyundai Pharm
2025-04-22 – 2028-12-31 · Hypertension, Primary Hypercholesterolaemia
What this study did
NCT07564726 · Celltrion Pharm, Inc.
2022-08-05 – 2024-02-13 · Hypertension, Hypercholesterolemia
What this study did
NCT04659070 · Hanlim Pharm. Co., Ltd.
2020-07-15 – 2022-05-19 · Primary Hypercholesterolemia, Hypertension
What this study did
NCT04161001 · Daewoong Pharmaceutical Co. LTD.
2019-11-20 – 2022-02-02 · Hypertension, Dyslipidemia
What this study did
NCT04158076 · Addpharma Inc.
2020-01-23 – 2021-01-14 · Hypercholesterolemia, Hypertension
What this study did
NCT03872232 · Addpharma Inc.
2019-02-26 – 2020-08-12 · Hypercholesterolemia, Hypertension
What this study did
NCT04074551 · Hanmi Pharmaceutical Company Limited
2019-07-16 – 2020-03-17 · Hypertension, Dyslipidemias
What this study did
NCT02251847 · IlDong Pharmaceutical Co Ltd
2014-07 – 2015-07 · Hypercholesterolemia
What this study did
NCT01420549 · Ache Laboratorios Farmaceuticos S.A.
2013-03 – 2014-11 · Hypercholesterolemia, Dyslipidemia
What this study did
Other / comorbidity
NCT05155137 · Hospital Moinhos de Vento
2021-12-20 – 2030-12-14 · Stroke, Cognitive Decline
What this study did
NCT06317051 · Kirby Institute
2024-12-16 – 2027-12 · HIV Infections, Weight Gain
What this study did
Phase 1 (3)
Atherosclerotic Cardiovascular Disease
NCT06578676 · Hyundai Pharm
2024-06-20 – 2024-11-30 · Type 2 Diabetes, Dyslipidemias
What this study did
Other / comorbidity
NCT03532854 · LG Chem
2018-05-28 – 2019-01-30 · Healthy Male Volunteers
What this study did
Phase 4 (2)
Atherosclerotic Cardiovascular Disease
NCT07255820 · Bahria University
2026-01-01 – 2026-06-30 · Type 2 Diabetes Mellitus, Hypercholesterolemia / Elevated LDL Cholesterol
What this study did
NCT03847506 · HK inno.N Corporation
2018-07-05 – 2020-12-02 · Hypertension, Hyperlipidemia
What this study did
Appears in other studies (22)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (3)
Atherosclerotic Cardiovascular Disease
NCT02586155 · Resverlogix Corp
2015-11 – 2021-06-21 · Diabetes Mellitus, Type 2, Coronary Artery Disease
What this study did
NCT02262143 · IlDong Pharmaceutical Co Ltd
2014-11 – 2017-06 · Mixed Dyslipidemias
What this study did
NCT01709500 · Regeneron Pharmaceuticals
2012-12 – 2015-01 · Heterozygous Familial Hypercholesterolemia
What this study did
Phase 2 (2)
Atherosclerotic Cardiovascular Disease
Other / comorbidity
NCT06102863 · Peking University People's Hospital
2023-04-01 – 2025-09-01 · Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I
What this study did
Phase 1 (10)
Other / comorbidity
NCT07565441 · Jemincare
2026-05-11 – 2027-02-28 · ADPKD (Autosomal Dominant Polycystic Kidney Disease)
What this study did
NCT07875842 · InventisBio Co., Ltd
2026-09-16 – 2026-12-31 · Healthy Subjects
What this study did
NCT07446400 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2026-03-31 – 2026-11-07 · Healthy Volunteers
What this study did
NCT07128888 · Gan & Lee Pharmaceuticals.
2025-09-24 – 2026-04-13 · Obesity or Overweight
What this study did
NCT06917508 · Enanta Pharmaceuticals, Inc
2025-03-13 – 2025-06-13 · RSV Infection, Drug Drug Interaction
What this study did
NCT06031454 · Guangdong Raynovent Biotech Co., Ltd
2023-09-01 – 2023-12-31 · Drug Drug Interaction
What this study did
NCT05954624 · Guangdong Raynovent Biotech Co., Ltd
2023-07-10 – 2023-11-30 · Drug Drug Interaction
What this study did
NCT04621669 · Jiangsu HengRui Medicine Co., Ltd.
2021-01-08 – 2021-09-08 · Drug-drug Interaction,SHR3680
What this study did
NCT01101568 · GlaxoSmithKline
2010-04-14 – 2010-06-24 · Diabetes Mellitus, Type 2
What this study did
Phase 4 (4)
Atherosclerotic Cardiovascular Disease
NCT06856772 · Tor Biering-Sørensen
2025-02-28 – 2028-03-28 · Cardiovascular Diseases (CVD), Drug Effect, Atherosclerosis Cardiovascular Disease
What this study did
NCT06338293 · Nanjing First Hospital, Nanjing Medical University
2024-03-15 – 2025-12-31 · Coronary Artery Disease
What this study did
NCT02305355 · Kuhnil Pharmaceutical Co., Ltd.
2009-02 – 2011-02 · Diabetes Mellitus, Type 2, Hypertriglycemia
What this study did
Other / comorbidity
NCT06785727 · Prof. dr. Nathalie van der Velde
2025-02-01 – 2029-07-01 · Ischemic Stroke, Transient Ischemic Attack
What this study did
Early phase / not applicable (3)
Other / comorbidity
NCT07704918 · University of Colorado, Denver
2026-10-19 – 2028-12 · Melanoma
What this study did
NCT03127631 · McMaster University
2015-10-21 – 2026-12-31 · Prostate Cancer, Cardiovascular Disease
What this study did
NCT06515652 · Hamdard University
2023-09-01 – 2024-08-30 · Metabolic Syndrome
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Atherosclerotic Cardiovascular Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Rosuvastatin: this drugApprovedSmall moleculeHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
Alirocumab (Praluent)ApprovedMonoclonal antibodyPCSK9Weak signal
NCT03510884: DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7)
NCT01709500: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis (From Baseline to Week 52): Alirocumab 75 mg/up to 150 mg -48.7 percent change (Standard Error 1.9) vs Placebo 2.8 percent change (Standard Error 2.8)
Bempedoic Acid (Nexletol)ApprovedSmall moleculeATP citrate lyasePartial signal
NCT02991118: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid -15.07 percent change (Standard Error 1.073) vs Placebo 2.35 percent change (Standard Error 1.446)
NCT02988115: Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline; Week 12): Bempedoic Acid -22.58% (Standard Error 1.29) vs Placebo -1.17% (Standard Error 1.421)
Bempedoic Acid / Ezetimibe (Nexlizet)ApprovedSmall moleculeATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe)Partial signal
NCT03337308: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC -36.2% (Standard Error 2.56) vs Bempedoic Acid 180 mg -17.2% (Standard Error 2.52) vs Ezetimibe 10 mg -23.2% (Standard Error 2.18) vs Placebo 1.8% (Standard Error 3.49)
Cangrelor (Kengreal)ApprovedSmall moleculeP2Y12 receptorPartial signal
NCT00385138: Death, MI or ischemia-driven revascularization at 48 h: 7.0% cangrelor (185/2654) vs 8.0% placebo (210/2641); OR 0.87, 95% CI 0.71 to 1.07; P=0.17. Both arms received clopidogrel 600 mg (CHAMPION PLATFORM, NEJM 2009). missed
Colchicine (cardiovascular) (Lodoco)ApprovedSmall moleculeMicrotubule/inflammasome (tubulin)not yet gradedNo reviewed efficacy summary in this indication
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
Evolocumab (Repatha)ApprovedMonoclonal antibodyPCSK9Partial signal
NCT02392559: Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08)
NCT02207634: Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score (Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).): Evolocumab 0.1134 Z score (95% CI 0.0449 to 0.182) vs Placebo 0.1206 Z score (95% CI 0.0535 to 0.1877)
Ezetimibe / Simvastatin (Vytorin)ApprovedSmall moleculeHMG-CoA reductase / NPC1L1Reliable signal
NCT00202878: Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Ezetimibe/Simvastatin 32.72% (95% CI 31.63 to 33.85) vs Simvastatin 34.67% (95% CI 33.56 to 35.81)
NCT00110435: Percent reduction in LDL-C from baseline at 6 weeks: ezetimibe/simvastatin 10/20mg -53.6% vs atorvastatin 10mg -38.3% (P<.001) and vs atorvastatin 20mg -44.6% (P<.001); ezetimibe/simvastatin 10/40mg -57.6% vs atorvastatin 40mg -50.9% (P<.001). Primary endpoint (percent change from baseline in LDL-C) significantly favored ezetimibe/simvastatin at both dose comparisons.
Icosapent Ethyl (Vascepa)ApprovedSmall moleculeOmega-3 fatty acid (EPA)Reliable signal
NCT01492361: Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization. (Total follow-up time of up to approximately 6 years.): AMR101 705/4089 vs Placebo 901/4090
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT04560998: Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Wegovy)ApprovedPeptideGLP-1 receptorReliable signal
NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801
Ticagrelor (Brilinta)ApprovedSmall moleculeP2Y12 receptorPartial signalFeatured results are non-efficacy only in this race
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
AG2304Phase 3Small moleculeHMG-CoA reductase / NPC1L1Partial signalNo reviewed efficacy summary in this indication
AlprostadilPhase 3Small moleculeProstaglandin E1 receptornot yet graded
NCT01263925: ClinicalTrials.gov results section for NCT01263925 ('Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication', UCB Pharma, Phase 3, enrollment 561/541 FAS, completed April 2011 -- matches this record exactly). Primary outcome: pain-free walking-distance ratio vs active comparator (pentoxifylline) across three periods; both treatments produced similar improvements with no clear superiority of either. phase 3 result · pivotal pending
Amlodipine / Valsartan / Atorvastatin (CJ-30061)Phase 3Small moleculeAngiotensin II receptor / Calcium channel / HMG-CoA reductasePartial signalNo reviewed efficacy summary in this indication
Beperminogene Perplasmid (HGF Plasmid) (Collategene)Phase 3Gene therapy / editingHGF (hepatocyte growth factor), Hepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
Cilostazol / Rosuvastatin (UI022 / UI023)Phase 3Small moleculePDE3 (phosphodiesterase 3) and HMG-CoA reductaseReliable signal
NCT07600385: KPAQ summary score change (FAS, n=257): test group 15.41 points (SD 14.18) vs control group 10.27 points (SD 14.70); between-group difference 5.14 points (P=0.004), test group superior.
DalcetrapibPhase 3Small moleculeCETPPartial signal
NCT00658515: Primary composite cardiovascular endpoint, dalcetrapib vs placebo: hazard ratio 1.04 (95% CI 0.93 to 1.16), P=0.52; trial stopped for futility (NEJM 2012). missed
NCT01059682: Nominal Change From Baseline to Study End in Coronary Percent Atheroma Volume (PAV) of the Target Coronary Artery Assessed by IVUS. (24 months): Dalcetrapib 0.6% (Standard Deviation 3.69) vs Placebo 0.5% (Standard Deviation 2.01)
Dapagliflozin (Farxiga / Forxiga)Phase 3Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
DWC202206 + DWC202207Phase 3Small molecule—Partial signalNo reviewed efficacy summary in this indication
EbronucimabPhase 3Monoclonal antibodyPCSK9Partial signal
NCT05255094: LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001).
Enlicitide (Lipfendra)Phase 3PeptidePCSK9Reliable signal
NCT05952856: Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001).
NCT05952869: Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24): Enlicitide Decanoate -58.2% (Standard Deviation 28) vs Placebo 2.6% (Standard Deviation 23.6)
Ezetimibe (Zetia)Phase 3Small moleculeDietary Cholesterol Absorption Inhibitor, NPC1L1Reliable signal
NCT00092586: Percent change in LDL-C: ezetimibe+statin -25.8% vs placebo+statin -2.7%; treatment difference -23.1 percentage points (P<.001)
NCT03867318: Proportion achieving LDL-C goal <=100 mg/dL at Week 14: 22% (ezetimibe 10mg + atorvastatin, n=305) vs 7% (atorvastatin dose-titration alone, n=316); P<.01
Fimasartan / Atorvastatin / Ezetimibe (BR1017)Phase 3Small moleculeAT1 receptor; NPC1L1; HMG-CoA reductasePartial signal
NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025).
HyzetimibePhase 3Small moleculeNPC1L1Partial signal
NCT03433196: LDL-C percent change from baseline (primary endpoint, week 12): -16.39% (95% CI -19.04 to -13.74) with hyzetimibe (HS-25, referred to in this paper as hybutimibe) + atorvastatin vs -6.75% (95% CI -9.48 to -4.02) with atorvastatin alone, P<0.0001
NCT03413462: 第12周试验组LDL-C较基线的变化率为(-10.23±13.58)%,显著优于对照组(4.34±15.88)%。
Inclisiran (Leqvio)Phase 3RNA / oligonucleotidePCSK9Partial signal
NCT04652726: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78)
NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52)
LaroprovstatPhase 3Small moleculePCSK9Reliable signal
NCT06173570: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo)
Laroprovstat / RosuvastatinPhase 3Small moleculePCSK9 (laroprovstat component) + HMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
LepodisiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT05565742: Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): 16 mg LY3819469 -39.0% ± 7.37 vs 96 mg LY3819469 -74.4% ± 2.16 vs 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) -93.7% ± 0.38 vs Placebo 3.1% ± 8.99; p=<0.001 (16 mg LY3819469 vs Placebo), p=<0.001 (96 mg LY3819469 vs Placebo), p=<0.001 (400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo)
Lerodalcibep (Lerochol)Phase 3Protein / enzyme therapeuticPCSK9Reliable signal
NCT04797104: LDL-C at Week 24: placebo-adjusted reduction of 58.61% (P<.0001); co-primary endpoint, mean of Weeks 22 and 24: placebo-adjusted reduction of 65.0% (P<.0001)
NCT05004675: LDL-C change from baseline at Day 270 (mITT): -53% with lerodalcibep vs -45.3% with inclisiran (P=0.0319); per-protocol: -55.4% vs -45.4% (P=0.005)
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
MuvalaplinPhase 3Small moleculeApolipoprotein(a) [apo(a)] kringle domain / apo(a)-apoB100 interactionPartial signal
NCT05563246: Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay (Baseline, Week 12): 10 mg LY3473329 -47.35% ± 4.811 vs 60 mg LY3473329 -81.57% ± 1.230 vs 240 mg LY3473329 -85.71% ± 0.927 vs Placebo 0.48% ± 6.382; p=<.001 (10 mg LY3473329 vs Placebo), p=<.001 (60 mg LY3473329 vs Placebo), p=<.001 (240 mg LY3473329 vs Placebo)
NL003Phase 3Gene therapy / editingHepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
ObicetrapibPhase 3Small moleculeCETPPartial signal
NCT05142722: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10mg -29.94% (Standard Error 1.104) vs Placebo 2.7% (Standard Error 1.571)
NCT05425745: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10 mg -36.05% (Standard Error 1.769) vs Placebo 0.25% (Standard Error 2.48)
Obicetrapib / Ezetimibe (Evlarco)Phase 3Small moleculeCETP, NPC1L1Partial signal
NCT06005597: Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564)
OlpasiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT04270760: Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 (Baseline and Week 36): Group 1: Olpasiran 10 mg Q12W -66.91% ± 1.78 vs Group 2: Olpasiran 75 mg Q12W -93.78% ± 1.78 vs Group 3: Olpasiran 225 mg Q12W -97.53% ± 1.82 vs Group 4: Olpasiran 225 mg Q24W -96.89% ± 1.85 vs Group 5: Placebo Q12W 3.60% ± 1.89; p=<0.001 (Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W), p=< 0.001 (Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W)
Ongericimab (Junshida)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT05325203: Percent change in LDL-C from baseline to week 24 (JS002-005/NCT05325203, HeFH, 135 patients): ongericimab 150mg Q2W -69.4% vs placebo (p<0.0001); ongericimab 450mg Q4W -80.6% vs placebo (p<0.0001)
NCT04781114: LDL-C percentage change from baseline to week 24 vs placebo: 150 mg Q2W -67.7% (95% CI -72.5% to -63.0%; P<0.0001); 300 mg Q4W -61.2% (95% CI -67.1% to -55.2%; P<0.0001).
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
PelacarsenPhase 3RNA / oligonucleotideApolipoprotein(a) mRNAPartial signal
NCT05305664: Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule (Up to Week 52): Pelacarsen (TQJ230) 0.16 Apheresis sessions received per week (IQR 0.04 to 0.25) vs Placebo 0.93 Apheresis sessions received per week (IQR 0.9 to 1)
Pemafibrate (Parmodia)Phase 3Small moleculePPAR-alphaPartial signalNo reviewed efficacy summary in this indication
PMR (cilostazol ER)Phase 3Small moleculePhosphodiesterase 3 (PDE3)Weak signalNo reviewed efficacy summary in this indication
PravafenixPhase 3Small moleculeHMG-CoA reductase / PPAR-alphaPartial signalNo reviewed efficacy summary in this indication
QLC7401Phase 3RNA / oligonucleotidePCSK9not yet gradedNo reviewed efficacy summary in this indication
RanolazinePhase 3Small moleculeCardiac late sodium current (late INa, Nav1.5)Partial signal
NCT00099788: The primary end point occurred in 696 patients (21.8%) in the ranolazine group and 753 patients (23.5%) in the placebo group (hazard ratio 0.92). missed
NCT01562041: Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index (Baseline up to Day 15): Ranolazine 500 mg — Test 1: 3.211 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.6553); Test 2: 2.822 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0289); Test 3: 3.228 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.891); Test 4: 2.502 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.8884); Change From Baseline in Maximum ST/Heart Rate Index: -0.605 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0482)
RecaticimabPhase 3Monoclonal antibodyPCSK9Reliable signal
NCT04844125: Change in LDL-C from baseline at Week 12: -54.4% recaticimab vs -4.5% placebo; treatment difference -49.8 percentage points (95% CI -55.8 to -43.9), P<0.0001
NCT04849000: LDL-C reduction vs placebo at the primary endpoint timepoint: 150 mg Q4W -49.6% (95% CI 44.2-54.9%); 300 mg Q8W -52.8% (95% CI 48.3-57.2%); 450 mg Q12W -45.0% (95% CI 41.0-49.0%); P<0.0001 for all comparisons.
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
SAL003Phase 3Monoclonal antibodyPCSK9Partial signalNo reviewed efficacy summary in this indication
Sarpogrelate (Anplag)Phase 3Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
SumecigrelPhase 3Small moleculeP2Y12 platelet receptorPartial signal
NCT03599284: Primary, inhibition of ADP-induced platelet aggregation (%IPA) at day 28: vicagrel 20/5 mg 30.19%, 24/6 mg 35.02%, 30/7.5 mg 45.61%, clopidogrel 32.55%; the paper reports these as comparable across all groups (P=0.0694) and sets no non-inferiority margin.
SYH2053Phase 3RNA / oligonucleotidePCSK9Partial signalNo reviewed efficacy summary in this indication
Tafolecimab (Sintbilo)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT04289285: LDL-C percent change from baseline to week 48, treatment difference vs placebo: -65.0% (97.5% CI: -70.2%, -59.9%) for tafolecimab 450 mg Q4W; -57.3% (97.5% CI: -64.0%, -50.7%) for 600 mg Q6W; both P < 0.0001
NCT04709536: Percent change in LDL-C from baseline to Week 12: tafolecimab -68.9% (SE 1.4%) vs placebo -5.8% (SE 1.8%); treatment difference -63.0% (95% CI -66.5% to -59.6%, P<0.0001)
ZiltivekimabPhase 3Monoclonal antibodyInterleukin-6Partial signal
NCT05021835: 3-point MACE (CV death, non-fatal MI, non-fatal stroke): HR 0.99 (95% CI 0.88-1.11) for ziltivekimab vs placebo. missed
NeovasculgenPhase 2/3Gene therapy / editingVEGF165 gene therapy (angiogenic plasmid)Partial signal
NCT03068585: Pain-free walking distance increased in the pCMV-vegf165 (Neovasculgen) treatment group by 110.4% at 6 months, versus no positive results in the standard-treatment control group
ABP-745Phase 2Small moleculeNLRP3 inflammasomenot yet gradedNo reviewed efficacy summary in this indication
ACP-01Phase 2Biologic (subtype unspecified)Autologous angiogenic cell precursor (ACP) therapyPartial signal
NCT02551679: Primary composite (de-novo gangrene, doubling of wound size, major amputation or death within 1 year): 12 of 46 participants on ACP-01 vs 3 of 21 on placebo, hazard ratio 2.046 (95% CI 0.577 to 7.255), p=0.258 (CT.gov posted results). missed
EDP167Phase 2RNA / oligonucleotideANGPTL3Weak signalNo reviewed efficacy summary in this indication
SYH2070Phase 2RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
ZhibitaiPhase 2BotanicalHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
ALN-APOC3Phase 1RNA / oligonucleotideApolipoprotein C-III (APOC3)Weak signalNo reviewed efficacy summary in this indication
UIC201604
Phase 1(overall)
Small moleculeHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
VERVE-201Phase 1Gene therapy / editingANGPTL3 gene (hepatocyte genomic DNA)not yet gradedNo reviewed efficacy summary in this indication
Omega-3-Carboxylic Acids (Epanova)DiscontinuedSmall moleculePeroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptornot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 67 furthest-along competitors are listed; 56 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(43 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Rosuvastatin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (6)
November 2026 (1)
Phase 1Healthy Adult ParticipantsRecruiting
Est. primary completion 2026-11-22 · NCT07820891 · CT.gov ↗
What to watch
December 2026 (5)
Phase 1Overweight,ObesityActive not recruiting
Est. primary completion 2026-12-05 · NCT07550816 · CT.gov ↗
What to watch
Phase 1Overweight, ObesityActive not recruiting
Est. primary completion 2026-12-07 · NCT06982131 · CT.gov ↗
What to watch
Phase 1Diabete Mellitus, Lipid ProfileNot yet recruiting
Est. primary completion 2026-12-30 · NCT07378293 · CT.gov ↗
What to watch
Phase 1Lipid Profile,Blood PressureNot yet recruiting
Est. primary completion 2026-12-30 · NCT07389304 · CT.gov ↗
What to watch
Phase 4Statin Therapy, Statin Adverse Reaction, StatinRecruiting
Est. primary completion 2026-12-31 · NCT06804980 · CT.gov ↗
What to watch
2027 (21)
January 2027 (2)
Phase 1Healthy ParticipantsActive not recruiting
Est. primary completion 2027-01-25 · NCT07534592 · CT.gov ↗
What to watch
Phase 4Atherosclerotic Cardiovascular DiseaseActive not recruiting
Est. primary completion 2027-01-28 · NCT03169985 · CT.gov ↗
What to watch
February 2027 (1)
Phase 1HealthyNot yet recruiting
Est. primary completion 2027-02-09 · NCT07862621 · CT.gov ↗
What to watch
March 2027 (4)
Phase 1TP53 Y220C Mutation, Advanced Solid TumorsRecruiting
Est. primary completion 2027-03 · NCT07372625 · CT.gov ↗
What to watch
Phase 1HealthyRecruiting
Est. primary completion 2027-03 · NCT07339722 · CT.gov ↗
What to watch
Phase 1Healthy Adult ParticipantsRecruiting
Est. primary completion 2027-03-09 · NCT07881224 · CT.gov ↗
What to watch
Phase 1HIV InfectionsNot yet recruiting
Est. primary completion 2027-03-12 · NCT07939594 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2/3Peripheral Nerve DiseaseNot yet recruiting
Est. primary completion 2027-04 · NCT07504198 · CT.gov ↗
What to watch
May 2027 (3)
Early phase / not applicableObesity & Overweight, Bariatric Surgery, Pharmacokinetics After Oral Intake, Drug AbsorptionNot yet recruiting
Est. primary completion 2027-05-15 · NCT07748273 · CT.gov ↗
What to watch
Phase 3Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2027-05-28 · NCT07619118 · CT.gov ↗
What to watch
Phase 1Primary Sclerosing Cholangitis, Inflammatory Bowel DiseasesRecruiting
Est. primary completion 2027-05-31 · NCT05912387 · CT.gov ↗
What to watch
June 2027 (3)
Phase 1Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral NeoplasmsRecruiting
Est. primary completion 2027-06 · NCT05614739 · CT.gov ↗
What to watch
Phase 1Healthy VolunteersRecruiting
Est. primary completion 2027-06-01 · NCT07629999 · CT.gov ↗
What to watch
Phase 4Atherosclerotic Cardiovascular DiseaseActive not recruiting
Est. primary completion 2027-06-01 · NCT05850091 · CT.gov ↗
What to watch
July 2027 (1)
Phase 3Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2027-07-30 · NCT07619131 · CT.gov ↗
What to watch
October 2027 (3)
Phase 3Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2027-10-11 · NCT07930507 · CT.gov ↗
What to watch
Phase 1Cholesterol; LipidosisRecruiting
Est. primary completion 2027-10-30 · NCT04903223 · CT.gov ↗
What to watch
Phase 1Crohn's Ileocolitis, Crohn DiseaseRecruiting
Est. primary completion 2027-10-31 · NCT06538649 · CT.gov ↗
What to watch
November 2027 (2)
Phase 4Atherosclerotic Cardiovascular DiseaseActive not recruiting
Est. primary completion 2027-11 · NCT06767345 · CT.gov ↗
What to watch
Phase 2Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2027-11-30 · NCT06488105 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Erectile Dysfunction Due to Arterial Disease, Atheroscleroses, Erectile Disfunction, Endothelial Dysfunction, Androgen Profile, TestosteroneRecruiting
Est. primary completion 2027-12 · NCT07460960 · CT.gov ↗
What to watch
2028 (9)
January 2028 (1)
Phase 3Venous Thromboembolism, Blood Clot, Post Thrombotic SyndromeRecruiting
Est. primary completion 2028-01 · NCT04319627 · CT.gov ↗
What to watch
April 2028 (1)
Phase 4Anthracycline-induced Cardiac Toxicity, Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer …Not yet recruiting
Est. primary completion 2028-04-21 · NCT07254221 · CT.gov ↗
What to watch
May 2028 (2)
Early phase / not applicableSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite AthletesEnrolling by invitation
Est. primary completion 2028-05-01 · NCT07568574 · CT.gov ↗
What to watch
Phase 2Clonal Cytopenia of Undetermined Significance, Myelodysplastic SyndromesRecruiting
Est. primary completion 2028-05-31 · NCT05483010 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2028-06-01 · NCT07474649 · CT.gov ↗
What to watch
September 2028 (2)
Phase 3Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2028-09-01 · NCT07736313 · CT.gov ↗
What to watch
Phase 4Intracranial Arteriosclerosis, Cognitive ImpairmentNot yet recruiting
Est. primary completion 2028-09-30 · NCT07605130 · CT.gov ↗
What to watch
December 2028 (2)
Phase 1ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-01 · NCT07912268 · CT.gov ↗
What to watch
Phase 1Healthy Male VolunteersNot yet recruiting
Est. primary completion 2028-12-15 · NCT07744386 · CT.gov ↗
What to watch
2029 (3)
February 2029 (1)
Phase 4Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2029-02-28 · NCT06186037 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic …Recruiting
Est. primary completion 2029-08-31 · NCT05832229 · CT.gov ↗
What to watch
September 2029 (1)
Phase 4Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2029-09 · NCT07799779 · CT.gov ↗
What to watch
2031 (4)
March 2031 (2)
Phase 4PRS-based Primary Prevention of CVDActive not recruiting
Est. primary completion 2031-03 · NCT06820086 · CT.gov ↗
What to watch
Phase 4Venous Thromboembolism, Cancer, Cardiovascular EventsRecruiting
Est. primary completion 2031-03-31 · NCT07303816 · CT.gov ↗
What to watch
July 2031 (1)
Phase 3Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2031-07 · NCT07232069 · CT.gov ↗
What to watch
September 2031 (1)
Phase 3Covert Brain InfarctionRecruiting
Est. primary completion 2031-09-30 · NCT07012629 · CT.gov ↗
What to watch

See the full readout calendar ↗